 "Natco's partner Mylan invalidates third Teva Copaxone patent in US")
Natco Pharma Limited on September 2, 2016 announced that the US Patent and Trademark Office (PTO) has ruled in favour of its marketing partner, Mylan, in its inter partes review (IPR) proceeding and found all claims of US Patent, which is owned by Yeda Research & Development Co Ltd and licensed to Teva Pharmaceuticals Industries Ltd, unpatentable. This is the third patent related to Copaxone 40 mg/mL (glatiramer acetate) to be found unpatentable in the last week.
On August, 24, 2016, the PTO's Patent Trial and Appeal Board (PTAB) found Teva's first two patents unpatentable in Mylan's IPR challenge of these patents.
Copaxone (glatiramer acetate) 40 mg dosage injection, used for the treatment of multiple sclerosis, had US sales of approximately $ 3.3 billion for the 12 months ending June 30, 2016, according to IMS Health.
Natco’s marketing partner Mylan believes it is one of the first companies to have filed a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification for a three times per week glatiramer acetate injection 40 mg/mL, and expects to be eligible for 180 days of marketing exclusivity in the US upon final FDA approval.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%